Actinium Pharmaceuticals (ATNM) Given a $3.00 Price Target by B. Riley Analysts
B. Riley set a $3.00 price objective on Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) in a research note published on Wednesday. The firm currently has a buy rating on the biotechnology company’s stock.
ATNM has been the topic of several other reports. Zacks Investment Research raised shares of Actinium Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, June 19th. Maxim Group reissued a buy rating and set a $3.00 target price on shares of Actinium Pharmaceuticals in a research report on Tuesday, August 14th. Five investment analysts have rated the stock with a buy rating, The stock presently has an average rating of Buy and a consensus price target of $3.75.
Shares of NYSEAMERICAN:ATNM opened at $0.63 on Wednesday. Actinium Pharmaceuticals has a 1 year low of $0.33 and a 1 year high of $0.85.
A number of institutional investors have recently bought and sold shares of ATNM. Worth Venture Partners LLC acquired a new position in Actinium Pharmaceuticals during the first quarter worth $140,000. Renaissance Technologies LLC grew its position in shares of Actinium Pharmaceuticals by 1,269.5% in the second quarter. Renaissance Technologies LLC now owns 387,500 shares of the biotechnology company’s stock valued at $248,000 after purchasing an additional 359,205 shares during the last quarter. Sio Capital Management LLC acquired a new stake in shares of Actinium Pharmaceuticals in the first quarter valued at about $393,000. Sabby Management LLC acquired a new stake in shares of Actinium Pharmaceuticals in the first quarter valued at about $729,000. Finally, Anson Funds Management LP acquired a new stake in shares of Actinium Pharmaceuticals in the first quarter valued at about $1,502,000.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.
Further Reading: Closed-End Mutual Funds (CEFs)
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.